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ARTICLE
Epidemiology
Breast cancer mortality in synchronous bilateral breast cancer
patients
Mathias Kvist Mejdahl1,2, Jan Wohlfahrt2, Marianne Holm3, Eva Balslev4, Ann Søegaard Knoop5, Anne Tjønneland3,6,
Mads Melbye2,7,8 and Niels Kroman1,9
BACKGROUND: Evidence suggests that patients with synchronous bilateral breast cancer (SBBC), diagnosed within 4 months, have
an inferior prognosis compared to unilateral breast cancer (UBC) patients. Using data from nationwide Danish clinical databases,
this cohort study investigated whether the inferior prognosis could be explained by SBBC patients having a more aggressive
disease, or whether the prognosis could be explained by the fact that they have two simultaneous cancers.
METHODS: Patients were diagnosed from 1999–2015. The main outcome was excess mortality, subtracting background population
mortality from observed mortality. Differences between SBBC and UBC patients were evaluated by rate ratios (RR) and estimated by
Poisson regression.
RESULTS: In total, 1214 SBBC and 59 177 UBC patients were included. SBBC patients had a significantly higher excess mortality than
UBC patients after adjustment for age and period (RR= 1.73; 95% CI:1.44–2.08; p < 0.01) and after adjusting for characteristics of the
worst tumour as traditionally done (RR= 1.31; 95% CI:1.08–1.57; p= 0.01). However, adjusting for characteristics of both tumours,
using a more advanced competing risks model, no difference was observed (RR= 1.01; 95% CI:0.83–1.22; p= 0.93).
CONCLUSIONS: Our study does not support that the inferior prognosis in SBBC patients is due to having more aggressive tumours
per se, but rather the combined effect of having two simultaneous cancers.
British Journal of Cancer (2019) 120:761–767; https://doi.org/10.1038/s41416-019-0403-z
BACKGROUND
Synchronous bilateral breast cancer (SBBC) is breast cancer
diagnosed more or less simultaneously in both breasts in the
same patient. The cut-off for synchronicity described in the
literature has usually been between 3 and 6 months.1 Evidence
supports viewing the two tumours in synchronous breast cancers
as two primary lesions and not as one disease with metastatic
spread.2,3 When comparing the prognosis of SBBC to that of
unilateral breast cancer (UBC), in most previous work, the method
has been to choose an index tumour, usually the prognostically
worst, the largest, or the first to be diagnosed, based on which to
compare the SBBC patient to the UBC patient.4–15 A meta-analysis
found a higher breast cancer mortality among SBBC patients
compared with UBC patients, with a pooled hazard ratio (HR) of
1.36 (95% CI 1.24–1.50).1 The approach of comparing SBBC to UBC
using the worst tumour as index in the SBBC patient makes sense
as the clinical consensus regarding the decision of adjuvant
treatment for SBBC patients today is based on the most adverse
tumour characteristics.9 But this approach does not offer an
explanation as to why SBBC patients potentially have an inferior
prognosis.
Our hypothesis was that the unexplained higher risk of breast
cancer death seen among SBBC patients when comparing them to
UBC patients based on their prognostically worst tumour could be
explained by the combined risk of the two tumours. The aim of
the current study was to analyse the prognosis of SBBC compared
to UBC in a large and nationwide cohort of Danish women with
detailed information on disease characteristics from both tumours.
METHODS
Registries
The Danish Breast Cancer Group (DBCG) database is a nationwide
clinical breast cancer database initiated in 1977.16 Previous quality
assessments of the database have shown a near complete
registration of breast cancer cases.17,18 Using the unique civil
registration number assigned to all Danish citizens, info on
diagnosis from the DBCG was linked to the Danish Pathology
Register, which contains detailed information on all human tissues
examined by a pathological department in Denmark.19 Informa-
tion on death and emigration was obtained by linkage with the
Civil Registration System.20
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Study population
All patients diagnosed with primary breast cancer in Denmark
from 01 January 1999 to 31 December 2015 were identified in the
DBCG database and screened for inclusion in the present study.
January 1999 was chosen as cut-off, as the Danish Pathology
Register is increasingly incomplete before this date. If patients
were diagnosed with bilateral breast cancer, with the two cancers
diagnosed within 4 months of each other, they were defined as
SBBC patients. The cut-off was in accordance with another
research group examining metachronous bilateral breast cancer
in Denmark.21 The exclusion criteria were patients with dissemi-
nated cancer at time of diagnosis, locally advanced cancer, only
ductal carcinoma in situ, previous malignancies (non-melanoma
skin cancer excluded), patients receiving neoadjuvant therapy,
patients not receiving surgical treatment, cancer of non-breast
parenchyma origin, or age <18 years. Further, SBBC patients were
excluded if they could not be identified with a breast cancer in the
Pathology Register or had occult cancer on one side (e.g. axillary
lymph node metastasis, but with no identified primary tumour in
the breast). SBBC patients otherwise not having disseminated or
locally advanced disease, were also excluded if the pathologist
specifically had described one side as likely being a metastasis
from the contralateral breast, as both UBC and SBBC patients with
metastatic disease were excluded from the study.
Disease characteristics and treatment
For UBC patients, data on patient characteristics, disease
characteristics, and mortality was retrieved from the DBCG
database. With SBBC patients, the policy has been only to register
the patients in the database and subsequently let them go off-
study. Thus, except for data on mortality and patient character-
istics, no follow-up data is available on this patient group, and
data on clinical and histopathologic characteristics are incon-
sistent in the DBCG database. For SBBC patients, detailed
histopathologic information was therefore retrieved from the
Danish Pathology Register.
Data on intention-to-treat (ITT) adjuvant protocol treatment was
for UBC patients retrieved from the DBCG database. In Denmark,
the DBCG publishes national multidisciplinary guidelines for
diagnostic, follow-up and treatment of breast cancer,22 and
patients are allocated to treatment protocols based on their risk
profile. For UBC patients who were not included in a DBCG
protocol and without missing data on disease characteristics,
adjuvant ITT treatment was estimated based on DBCG treatment
algorithms. Adjuvant treatment of SBBC patients is not registered
in the DBCG database and was therefore defined according to
DBCG treatment guidelines, and the general practice in Denmark
for treatment of SBBC patients. In Denmark, the consensus is to
perform risk stratification of SBBC patients based on the worst
disease characteristics regardless of side. In the multivariable
analyses, surgery and ITT radiotherapy were combined in a
variable with three levels: mastectomy, mastectomy and radio-
therapy, and breast conserving surgery (BCS) and radiotherapy.
Supplement 1 shows a table with description, categorisation, and
source of the data included in the study.
Statistical analysis
Differences in histopathologic characteristics between SBBC and
UBC patients were evaluated using logistic and multinomial
regression analyses, with correlation between the right and left
tumour in the same SBBC patient accounted for by a Generalised
Estimating Equation correlation structure.
The excess mortality, where the observed mortality is sub-
tracted from the expected mortality based on background
population mortality rates, was used as a measure of breast
cancer related death. The difference in excess mortality between
women with SBBC compared to UBC was evaluated by rate ratios
(RR) estimated by Poisson regression with expected mortality as
offset using PROC NLMIXED in SAS. The statistical model is
described in detail in supplement 2. The expected mortality was
calculated by multiplying the person years at risk according to age
(1 year) and time-period (5 years) with population mortality rates
from Statistics Denmark. Patients were followed from primary
surgery until death, emigration or end of follow-up (01 August
2017). For SBBC patients, first surgery date was used if surgery of
the two tumours was not performed on the same day.
The excess mortality was adjusted in several ways. Initially, a
model adjusting only for time-period (5-year intervals), age (5-year
intervals), and time since diagnosis (1-year intervals) for both UBC
and SBBC patients was applied. Subsequently, disease character-
istics (tumour size, malignancy grade, histological subtype, nodal
involvement, and ER-status) and treatment variables (ITT che-
motherapy, and surgery/ITT radiotherapy) were added. Adjust-
ment in UBC patients was performed using a traditional log-linear
modelling of the rate by disease characteristics and treatment. For
SBBC patients, adjustment was performed using three different
ways to define the characteristics of the two tumours: the
characteristics of the worst tumour, the worst disease character-
istics regardless of side, and the characteristics of both tumours.
Using the characteristics of the worst tumour, the rate for SBBC
patients was modelled by a log-linear approach, and the disease
characteristic and loco-regional therapy in a SBBC patient was
defined by selecting the largest tumour, and if equal size, then by
axillary lymph node metastases, histological subtype, and finally
by tumour grade. Using the worst disease characteristics, the
disease characteristic in a SBBC patient was defined by the disease
characteristic of the à priori worst prognostic outcome regardless
of side. If loco-regional treatment between the two sides differed
in the SBBC patients, mastectomy and radiotherapy were chosen
above the other loco-regional treatments, and mastectomy above
BCS and radiotherapy. Finally, using the characteristics of both
tumours, the two tumours in a SBBC patient were treated as
competing risk for the excess mortality in the Poisson model, i.e.,
the rate in SBBC patients was modelled as a sum of two
components both modelled by an exponential function of a linear
form of the covariates for the two tumours.
Observed cumulative mortality rates were calculated as number
of events divided by person years at risk in 1-year intervals and
cumulated by 1 year intervals and predicted cumulative mortality
rates were calculated using the model based predicted number of
events.
To address missing data, a multiple imputation (MI) analysis by
fully conditional specification methods was used to predict values
of missing data (see supplement 3). A total of 20 imputations were
performed. Using Rubin’s MI strategy, the imputed data sets were
combined to produce inferences for the parameters in the models.
Data was analysed using SAS version 9.4 (SAS institute Inc., Cary,
USA).
RESULTS
In the DBCG database, from 01 January 1999 to 31 December
2015, 1 659 patients were registered with SBBC. Among these, 1
214 SBBC patients were included in the study. For UBC patients, 59
177 patients out of 68 376 were included. Figure 1 shows the flow
chart of causes for exclusion. For disease and patient character-
istics see Table 1, and for treatment characteristics see Table 2.
SBBC patient were older than UBC patients, and the distribution of
all disease characteristics were statistically different from UBC
patients, with the worst tumour in SBBC patients generally being
larger and with more nodal involvement, and more often ER
positive and lobular. SBBC patients more often received a
mastectomy and were less often allocated to chemotherapy and
radiotherapy.
SBBC patients contributed 8 924-person years at risk with 454
patients dying during follow-up. UBC patients contributed 465
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090-person years at risk, and 16 096 patients died during follow-
up. The median follow-up time for the entire cohort was 7.23 years
(IQR: 3.97–11.10), with slightly shorter follow-up time for SBBC
patients (median: 6.79 years) than UBC patients (median: 7.24
years). The 5- and 10-year overall survivals for SBBC patients were
80.7% (95% CI: 78.3–82.9%) and 56.7% (95% CI: 53.3–60.0%), and
for UBC patients 85.1% (95% CI: 84.8–85.4%) and 70.5% (95% CI:
70.0–70.9%). In supplement 4, the Kaplan-Meier plot with 95% CI
bands is shown for SBBC and UBC patients, and Fig. 2 shows the
observed cumulative mortality rates for SBBC and UBC patients.
The RR for excess mortality of SBBC compared to UBC was 1.73
(95% CI: 1.44–2.08; p < 0.01) when adjusting for age, time-period,
and time since diagnosis (see Table 3), i.e. the mortality, beyond
the level in the population, was 73% higher in SBBC patients
compared to UBC patients. Adjusting for the characteristics of the
worst tumour, the RR was 1.31 (95% CI: 1.08–1.57; p= 0.01) and
adjusting for the worst disease characteristics regardless of side,
the RR was 1.17 (95% CI: 0.97–1.42; p= 0.10). Figure 3a shows the
predicted cumulative mortality rates for SBBC patients estimated
based on the characteristics of the worst tumour plotted against
the observed cumulative mortality rates. In patients with a risk
profile that would elicit chemotherapy, the RR was 1.37 (95% CI:
1.03–1.83), and for patients that should not receive chemotherapy,
the RR was 1.05 (95% CI: 0.81–1.37). The two RRs were not
significantly different (p= 0.18).
In Fig. 3b the predicted cumulative rates for expected mortality
and the contribution of the right and left tumour on excess
mortality were plotted against the observed cumulative mortality
rates. The residual effect of bilateral disease when adjusting for
characteristics of both tumours was RR= 1.01 (95% CI: 0.83–1.22;
p= 0.93).
The results were similar when using imputation to take missing
characteristics into account (see supplement 3).
DISCUSSION
In the present study we found that the excess mortality is around
30% higher among SBBC patients compared to UBC patients when
the comparison is based on characteristics of the prognostically
worst tumour. The worst tumour in the SBBC patient is more often
larger, and with more nodal involvement than the disease in the
UBC patient explaining why adjustment for these characteristics
changes the point estimate from 1.73 to 1.31. In the model
comparing SBBC patients to UBC patients based on the most
adverse disease characteristics regardless of side, the excess
mortality was around 20% higher among SBBC patients, although
not reaching statistical significance. In the ‘two tumour model’, the
excess mortality among SBBC patients could be attributed to the
combined mortality of the two cancers.
The excess mortality in SBBC patients when adjusting for the
characteristics of the worst tumour is comparable with previous
findings. The meta-analysis on the impact of SBBC on breast
cancer mortality showed a more than 30% higher mortality of
SBBC compared to UBC.1 This result was especially driven by one
larger study using data from the Surveillance, Epidemiology, and
End Results database from the NIH.1,23 This study showed a
relative risk for breast cancer death around 1.45 when
comparing SBBC to UBC.23 Patients were diagnosed from
1973–2000, and for disease characteristics, only adjustment for
histological subtype and stratification on stage was per-
formed.23 Two other large studies, where patients were also
diagnosed before 2000, reported similar results,10,11 and one
large (n= 837) and more recent study, that included adjust-
ments for more detailed disease characteristics, reported a
hazard ratio of 1.17 (95% CI: 0.91 to 1.51), which is slightly lower
than the findings from the present study.4 During the last 30
years the prognosis of breast cancer has improved substantially,
and the treatment of breast cancer has also changed consider-
ably with more adjuvant treatment and less extensive surgery.16
The generalisability of the results from studies with patients
diagnosed in the 90’s and earlier to patients today is therefore
questionable. Further, these earlier studies only made rather
crude adjustments for disease characteristics.10,11,23 As shown in
the present study, the effect of SBBC on excess mortality
changes considerably when adjustments for detailed disease
characteristics are included.
Patients identified in DBCG database with
synchronous bilateral breast cancer
diagnosed within four months. From 01
January 1999 to 31 December 2015:
N = 1659
Exclusions:
Total: N = 445
Disseminated or locally advanced cancer: N = 80
Neoadjuvant therapy: N = 98
Biopsy only: N = 125
Other malignancies before SBBC: N = 67
DCIS only on one or both sides: N = 52
Not found in pathology registry: N = 8
Metastasis from one breast to the other: N = 4
Other causes: N = 11
Patients identified in DBCG database with
unilateral breast cancer from 01 January
1999 to 31 December 2015:
N = 68,376
SBBC patients included in analysis:
N = 1214
Exclusions:
Total: N = 9199
Disseminated/locally advanced cancer: N = 2727
Neoadjuvant therapy: N = 1894
Biopsy only: N = 2952
Other malignancies before UBC: N = 1401
DCIS/phyllodes/LCIS: N = 78
Not carcinoma (e.g. sarcoma): N = 101
Age<18: N = 2
Event before registered treatment: N = 44
UBC patients included in analysis:
N = 59,177
Fig. 1 Flow chart. DBCG Danish Breast Cancer Group, DCIS ductal carcinoma in situ, LCIS lobular carcinoma in situ, SBBC synchronous bilateral
breast cancer, UBC unilateral breast cancer
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Table 1. Patient and disease characteristics of unilateral and synchronous bilateral breast cancer patients
Unilateral breast cancer Synchronous bilateral breast cancer p-valuea
Total, N 59177 1214
Age, N (%) <0.01
<40 years 2219 (3.8) 16 (1.3)
40–49 years 8051 (13.6) 92 (7.6)
50–59 years 15164 (25.6) 214 (17.6)
60–69 years 18275 (30.9) 412 (33.9)
≥70 years 15468 (26.1) 480 (39.5)
Menopausal status, N (%) <0.01
Pre-menopausal 14362 (24.4) 164 (13.6)
Post-menopausal 44619 (75.6) 1043 (86.4)
Missing (% missing) 196 (0.3) 7 (0.6)
Unilateral Worst tumourb Contralateral tumour
N % N % N %
Histology <0.01
Ductal 47931 81.2 956 78.7 959 79.0
Lobular 6417 10.9 189 15.6 166 13.7
Other 4709 8.0 69 5.7 89 7.3
Missing (% missing) 120 (0.2) 0 (0.0) 0 (0.0)
Oestrogen receptor status <0.01
Positive 48801 83.3 1083 89.7 1107 92.9
Negative 9792 16.7 125 10.3 85 7.1
Missing (% missing) 584 (1.0) 6 (0.5) 22 (1.8)
Combined HER2− & ER− status
(≥01 Jan 2007)
33682 56.9 649 53.5 649 53.5 <0.01
ER+/HER2− 24315 76.7 501 81.1 553 90.4
ER+/HER2+ 2828 8.9 56 9.1 26 4.2
ER− /HER2+ 1425 4.5 22 3.6 9 1.5
ER− /HER2− 3124 9.9 39 6.3 24 3.9
Missing (% missing) 1990 (5.9) 31 (4.8) 37 (5.7)
Malignancy grade <0.01
I 16035 30.7 371 33.9 507 48.1
II 23511 45.1 532 48.7 465 44.1
III 12630 24.2 190 17.4 82 7.8
Missing (% missing) 7001 (11.8) 121 (10.0) 160 (13.2)
Tumour size <0.01
0–20mm 36596 62.2 553 45.8 1052 89.0
21–50mm 20440 34.7 593 49.1 126 10.7
>50mm 1798 3.1 62 5.1 4 0.3
Missing (% missing) 343 (0.6) 6 (0.5) 32 (2.6)
Nodal involvement <0.01
0 metastases 32152 55.9 548 47.0 847 74.0
1–3 metastases 17090 29.7 403 34.6 232 20.3
4–9 metastases 5170 9.0 127 10.9 49 4.3
>9 metastases 3131 5.4 88 7.5 17 1.5
Missing (% missing) 1634 (2.8) 48 (4.0) 69 (5.7)
ER-status oestrogen receptor status, HER2-status human epidermal growth factor receptor 2 status, SBBC synchronous bilateral breast cancer, UBC unilateral
breast cancer, y years
aTest for difference in the distribution of disease and patient characteristics between unilateral and synchronous bilateral breast cancer patients using logistic
and multinomial regression analyses. For bilateral breast cancer patients, information on disease characteristics from both sides were used, taking account of
within patient correlation using a GEE correlation structure. Excluding missing values
bThe worst tumour was selected based on size, then nodal involvement, then histological subtype, and then malignancy grade
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When adjusting for disease characteristics of both tumours we
found no excess mortality in SBBC patients. The hypothesis of
viewing SBBC as a simple competing risk model with two breast
cancers ‘competing to be fatal to the patient’ is very plausible. The
model does however assume that the effects on breast cancer
mortality attributed by each of the two tumours in a SBBC patient
are independent of each other. So hypothetically, if we radically
removed only the left tumour by surgery and did not treat the
right tumour, this procedure should not influence the natural
course of the right tumour. Although it is a strong assumption,
viewing the tumours as acting independently on breast cancer
mortality appears to be a good approximation of the prognosis of
bilateral breast cancer patients in the present study. Two studies
have tried to analyse the prognosis incorporating information
from both tumours, one by describing the effect of concordance
in tumour stage on prognosis,23 and another describing the effect
of concordance in oestrogen receptor status on prognosis.24
These studies showed that characteristics of both tumours are of
importance in determining the prognosis for a SBBC patient, and
the present study further adds to this assumption by showing that
the two tumours each has the same effect on the excess mortality
as an equivalent unilateral cancer. The reason why the ‘worst
tumour model’ only gives a 30% higher excess mortality and not a
double risk, is because SBBC patients usually present with a large
index tumour and a smaller contralateral tumour as supported by
the present data. In Denmark it is a standard procedure to perform
bilateral mammography and ultrasound when a breast cancer is
diagnosed, and a subclinical contralateral lesion would therefore
usually be detected during diagnostic evaluation. In a study on the
incidence of bilateral breast cancer, Hartman et al. showed that
the incidence of SBBC was higher than what could be explained
by chance, and they hypothesised that a more susceptible group
of women were involved in SBBC.25 Also, a study by Kwast et al.
showed that women with bilateral breast cancer had a higher risk
of a third primary cancer of non-breast origin.26 Based on the
current findings, one could argue that the increased risk of a third
primary disease and the potential susceptibility to breast cancer
formation does not seem to have an impact on the excess
mortality in itself, as the excess mortality could be explained by
the two breast cancer lesions in the SBBC patient.
It has been suggested that SBBC patients might not be
optimally treated with adjuvant therapy,1 and that bilateral
disease should be added as a prognostic indicator when
determining allocation to adjuvant treatment.1,13 The ‘worst
characteristics model’ only gives a slightly increased excess
mortality (RR= 1.17), although not reaching statistical significance,
and when dividing SBBC patients based on allocation to
chemotherapy, no difference in the impact of bilateral disease
on excess mortality could be observed. It should be noted though,
that these findings are limited by a lack of power.
The present study is one of the largest studies to date on the
prognosis of SBBC, and the largest with detailed information on
disease characteristics. The use of excess mortality could both be
viewed as a strength and a limitation. Establishing the cause of
death can be difficult, and autopsies are not performed on a
routine basis in Denmark. On the other hand, when using excess
mortality, it is assumed that the cause of death we are
investigating is rare in the general population as these deaths
are included in the deaths observed in the general population.
One limitation is that we did not have definitive information on
adjuvant treatment. Instead treatment was estimated based on
DBCG guidelines and for SBBC patients on treatment-consensus.
But adherence to guidelines of breast cancer treatment in
Denmark is considered high.22 Another limitation is missing data
potentially introducing bias. This was addressed in our multiple
imputation analysis. Here the RR for excess mortality of SBBC was
attenuated slightly, although the interpretation of the results did
not change.
In conclusion, the present study has shown that patients with
SBBC have a 30% higher excess mortality than UBC patients when
the comparison is based on the largest tumour in the SBBC
patient, but when taking the characteristics of both tumours into
account, no difference in excess mortality between SBBC and UBC
patients was found. The study does therefore not support that
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Fig. 2 Observed cumulative mortality rates of synchronous bilateral
( ) and unilateral ( ) breast cancer patients
Table 2. Treatment characteristics based on DBCG treatment










N % N % N %
Surgery
Mastectomy 25900 43.8 746 61.5 667 55.0
Breast conserving surgery 33277 56.2 468 38.6 545 45.0
Missing (% missing) 0 (0.0) 0 (0.0) 2 (0.2)
Radiotherapya
Yes 40965 76.4 639 63.1 580 57.3
No 12685 23.6 374 36.9 433 42.7
Missing (% missing)b 5527 (9.3) 201 (16.6) 201 (16.6)
Chemotherapya N %
Yes 22236 41.4 335 33.1
No 31430 58.6 678 66.9
Missing (% missing)b 5511 (9.3) 201 (16.6)
Endocrine therapya
Yes 36023 67.1 883 87.2
No 17643 32.9 130 12.8
Missing (% missing)b 5511 (9.3) 201 (16.6)
DBCG Danish Breast Cancer Group, SBBC synchronous bilateral breast
cancer, UBC unilateral breast cancer
aFor UBC patients, intention-to-treat allocation based on DBCG protocols is
shown. For SBBC patients, adjuvant treatment is estimated based on
consensus-treatment for complete cases
bFor SBBC patients, missing data is due to non-complete cases for tumour
characteristics, and for UBC patients missing data is for patients not
included in a DBCG protocol
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